# Hutchmed

Source: https://onco.cc/companies/hutchmed/  
OnCo record `hutchmed` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.

## Summary

Shanghai discovery engine with three NMPA-approved originals: fruquintinib (colorectal 2018; FDA approval November 2023 after Takeda licensed ex-China rights for $400 million upfront), surufatinib (neuroendocrine tumours 2020) and savolitinib (MET exon 14 NSCLC 2021, with AstraZeneca). Also sovleplenib (Syk) and tazemetostat rights in China. Its FDA approval of fruquintinib in a global population (FRESCO-2) showed the route Chinese drugs must take: a multiregional confirmatory trial.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: HUTCHMED (China); Hutchison China MediTech; Chi-Med; 和黄医药; Hutchison Medipharma; HUTCHMED
- Tags: china
- HQ: Hong Kong / Shanghai
- Type: biotech
- Website: https://www.hutch-med.com/
- Ticker: HCM / 13.HK

## Sources

- Official website: https://www.hutch-med.com/

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [HMPL-306](https://onco.cc/drugs/hmpl-306/), [HMPL-453](https://onco.cc/drugs/hmpl-453/), [HMPL-760](https://onco.cc/drugs/hmpl-760/), [IAH0968](https://onco.cc/drugs/iah0968/), [LB1410](https://onco.cc/drugs/lb1410/), [LB4330](https://onco.cc/drugs/lb4330/), [Savolitinib](https://onco.cc/drugs/savolitinib/), [Surufatinib](https://onco.cc/drugs/surufatinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Takeda](https://onco.cc/companies/takeda/)
- trials: [A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors](https://onco.cc/trials/nct07228247/), [A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06361888/), [A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL](https://onco.cc/trials/nct07409428/), [A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia](https://onco.cc/trials/nct06387069/), [Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct05009836/), [FRESCO](https://onco.cc/trials/fresco/), [FRESCO-2](https://onco.cc/trials/fresco-2/), [HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct04353375/), [HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct07396584/), [Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib](https://onco.cc/trials/nct03778229/), [SANET-ep and SANET-p](https://onco.cc/trials/sanet/), [Savolitinib vs. Sunitinib in MET-driven PRCC.](https://onco.cc/trials/nct03091192/), [Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer](https://onco.cc/trials/nct06584032/), [Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL](https://onco.cc/trials/nct06601504/), [To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer](https://onco.cc/trials/nct06504732/)
- people: [Samantha Du (Du Ying)](https://onco.cc/people/du-samantha/), [Weiguo Su](https://onco.cc/people/su-weiguo/)
- key papers: [Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)](https://onco.cc/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/)

---
JSON: https://onco.cc/api/v1/entities/hutchmed.json